High Intensity Interval gait training for Gait

Phase-Based Progress Estimates
Hunter College, New York, NY
Gait+2 More
High Intensity Interval gait training - Behavioral
All Sexes
What conditions do you have?

Study Summary

This trial will compare the effects of high intensity interval gait training (HIIGT) to traditional moderate intensity continuous gait training (MICGT) in people with MS who have difficulty walking. High Intensity Interval gait training is a treatment for Gait that has previously been approved by the FDA for a different condition. Unlike other trials, no patients in this trial will receive a placebo.

Eligible Conditions

  • Gait

Treatment Effectiveness

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 10 minutes

10 minutes
Finctional gait assessment
6 minutes
6 minute walk test

Trial Safety

Trial Design

2 Treatment Groups

1 of 2
1 of 2
Active Control
Experimental Treatment

30 Total Participants · 2 Treatment Groups

Primary Treatment: High Intensity Interval gait training · No Placebo Group · N/A

Experimental Group · 1 Intervention: High Intensity Interval gait training · Intervention Types: Behavioral
ActiveComparator Group · 1 Intervention: Moderate paced continuous gait training · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 10 minutes
Closest Location: Hunter College · New York, NY
Photo of New York 1Photo of New York 2Photo of New York 3
2011First Recorded Clinical Trial
0 TrialsResearching Gait
6 CompletedClinical Trials

Who is running the clinical trial?

City University of New YorkLead Sponsor
9 Previous Clinical Trials
4,694 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
The study will compare the effects of a new intervention on participants with MS to a standard intervention.
You are able to walk for 6 minutes continuously with or without assistive device.
You are above the age of 18 because you have to be able to give consent for the study.
We do not have the resources to translate for the multiple sessions this study entails.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.